Browse Newsroom

InsuLife Appoints Dr. Olav Flaten as Chief Medical Officer

May 7, 2022

InsuLife is pleased to announce the appointment of Dr. Olav Flaten as Chief Medical Officer. Dr. Flaten was Medical Director in GSK Norway for 27 years. Before retiring from GSK, he was interim Medical Director in Sweden for one year and in Portugal for a year. Since leaving GSK, he has been working as a consultant and Board Director in several biotech and medtech companies. He brings valuable knowledge, skills, and experience both regarding medical governance and clinical trials. This will be of utmost importance for InsuLife when planning the phase 1 clinical trial and developing the clinical plan for INS-2301.

Dr. Flaten was trained as a Medical Doctor at the University of Oslo and worked at Ullevaal Hospital for seven years, specializing in Gastroenterology, during which time he also graduated as PhD. He has been on evaluation committees for Research Council Norway for 20+ years and has served as a Board Director of the Norwegian Drug Liability Association. Before joining GSK, he was Medical Director at Apothekernes Laboratorium, a Norwegian pharma company.

"We are proud to announce that Dr. Olav Flaten has joined the InsuLife team as Chief Medical Officer. Olav will strengthen our team with medical knowledge and scientific research experience, as well as pharma industry competence built during his career. We really look forward to working with him," says Aage Naerdal, CEO of InsuLife.

Subscribe for InsuLife News Updates
Sign up to receive the latest InsuLife news, updates and investing information delivered right to your inbox.
Newsletter Form (#1)
InsuLife is a Norwegian company aiming at bringing the unparalleled developmental INS-2301 skin-applied insulin to market.
Learn More
© Copyright 2024 - InsuLife AS, All Rights Reserved